



AGAR Executive Meeting Minutes – Monday 17th May, 2021

Venue: Quest Melbourne Airport Hotel, 20 Annandale Rd, Melbourne Airport.

***Attachments are available on the AGAR Website in the Executive Members Section.**

Attendees:

Elected Members:

Geoff Coombs (GC) – Chair

Graeme Nimmo (GN) – Deputy Chair (via Zoom)

Tom Gottlieb (TG)

Morgyn Warner (MW)

Peter Collignon (PC) (via Zoom)

Jon Iredell (JI)

Louise Cooley (LC)

Scientific Officers:

Denise Daley (DD) – Minutes Secretary/AGAR Scientific Officer

Jan Bell (JB) – AGAR Scientific Advisor

4.2	AGAR 2021 10 March 2021 CBH* Cairns were unable to re-join in 2021 due to staffing shortages, but plan to in 2022.	
4.3	AGAR 2021 10 December 2020 RMH* RMH have joined AGAR and have started submitting data.	
4.4	2019 AGAR Sepsis Outcome Programs Report ACSQHC* This report is on the website	
4.5	Preliminary Reports DoH* These were submitted on time to the DOH.	
4.6	Letter – CEO ACSQHC* A letter was received from the Commission thanking AGAR	
4.7	GLASS 2021 Feedback Form – Methods for Estimating Attributable Mortality*	
5.	AGAR Operating Procedures 2021* Some minor changes were made to the Operating Procedures 2020, these included the funding source.	
6.	AGAR 2020 Data Management Plan* No changes to this document. GN advised of his retirement on 18/7/2021 and therefore his resignation from AGAR, the AGAR Data Governance committee and ASA. LC will be the new chair of the AGAR Data Governance committee.	
7.	Financial Reports GC presented the following reports:	
7.1	December 2020 AGAR Quarterly Financial Report*	
7.2	March 2021 AGAR Quarterly Financial Report* These reports have been reviewed by the ASA committee.	
8.	AGAR 2019 Program	
8.1	AGAR 2019 Amalgam Report (ACSQHC)* This has been submitted and will feed into the 2021 AURA report.	

<p>9. 9.1 9.2 9.3 9.4 9.5</p>	<p>ACSQHC AGAR 2020 ACSQHC Contract* AGAR AESOP 2020 Progress Report* AGAR ASSOP 2020 Progress Report* AGAR GNSOP 2020 Progress Report* AGAR 2020 Grant Acquittal 01072020 to 3112200*</p> <p>All deliverables have been met and the progress reports submitted.</p>	
<p>10. 10.1 10.2 10.3 10.4 10.5 10.6 10.7 10.8 10.9 10.10 10.11 10.12 10.13 10.13.1 10.14 10.15 10.16</p>	<p>Department of Health Update Karin Thursky from NAPS was invited to join the meeting by zoom</p> <p>AGAR 2020 Approach to Market* GC is working on the ATM which is due for submission on 26th May 2021.</p> <p>AGAR 2020 Signed Letter of Offer*</p> <p>AGAR 2020 Signed COI*</p> <p>AGAR 2020 Project Plan*</p> <p>AGAR 2020 DoH Contract*</p> <p>AGAR 2020 Additional Projects*</p> <p>One off Funding Proposals* GC has submitted three one-off project proposals for ASSOP and GNSOP.</p> <p>One off Funding Proposal Response*</p> <p>2020-21 Budget - Australia’s National Antimicrobial Resistance Strategy Measure*</p> <p>Annual Statement of Financial Compliance*</p> <p>Agenda for AGAR One on One Meeting* GC and DD met with the DOH by zoom</p> <p>Presentation for AGAR One on One Meeting*</p> <p>AURA Program Partners Face to Face Meeting and Contracts*</p> <p>AURA Program Partners Face to Face Meeting Agenda* This meeting is in Canberra on 20th May 2021. GC, JI, DD and JB will attend.</p> <p>Deliverables between Now and June 2021*</p> <p>Comments on Deliverables*</p> <p>Insurance*</p>	

<p>11. 11.1 11.2 11.3 11.4</p>	<p>AGAR 2020 Program 2020 AGAR Program Budget* ASSOP 2020 Update (DD) Data and isolates have been received from all labs except QCH – no data or isolates for Q3 and Q4 2020. 2,718 <i>S. aureus</i> episodes have been received (a reduction from 3,157 episodes in 2019) 18% MRSA. All confirmatory tests have been completed, 470 MRSA have been sent for WGS with results received for 288. The remaining 182 will be available for the final report. AESOP 2020 Update (DD) Data and isolates have been received from all labs except QCH – no data or isolates for Q3 and Q4 2020. 1,229 enterococcal episodes have been received (1,327 in 2019). 39.7% <i>E. faecium</i>, 33.2% vancomycin resistant. 11.9% <i>vanA</i>, 16.6% <i>vanB</i>. There were 43.8% <i>E. faecium</i> in 2019 with 58.4% vancomycin resistance. 475 <i>E. faecium</i> have been sent for WGS, with results received for 401. The remaining 74 will be available for the final report. All confirmatory tests have been completed. GNSOP 2020 Update (JB) 8,742 episodes have been received. No data or isolates for Q3 and Q4 2020 from QCH. Total numbers and resistance trends are similar to 2019 except for an increase in 3rd gen cephalosporin resistance in the NT (27% in <i>K. pneumoniae</i>) 1,285 isolates have been selected for referral to WH, 1,204 have been received by WH. PCR and WGS results will be available for the final report.</p>	
<p>12. 12.1 12.2 12.3 12.4</p>	<p>AGAR 2021 Program 2021 AGAR Laboratories* JR will ask the Mater Hospital in Townsville, GC will contact Monica Lahra re POW and Gabriella O’Kane from Gosford Hospital, (Post meeting - Monica Lahra agreed to POW joining AGAR in 2022) 2021 – 2023 AGAR Program Budget GC is working on a 3 year program budget for AGAR. AESOP 2021 Update (DD) First quarter data was due on 14th May, to date have we have received 147 episodes from 12 labs, and will start WGS when the 2020 program is complete. ASSOP 2021 Update (DD) 357 episodes have been received from 10 labs</p>	<p>JR, GC</p>

12.5	GNSOP 2021 Update (JB) 1,106 episodes have been received from 17 labs.	
12.6	Date of admission (DD) There was a request from Andrew Gador-Whyte (SVH) for clarification on admission dates when a patient has blood cultures collected in ED, is then discharged and then recalled for treatment and ward admission. The ED date is the date of collection, then the recall admission is the date of admission and discharge, a comment should be added "patient recalled".	
13	AGAR Website No changes have been made to the website, all reports have been uploaded.	
14.	AGAR Data Entry Program The Database has been cleaned up, new rules have been written with warnings for incorrect dates and incorrect AST abbreviations, labs can now see the AST acceptable list and DD can see individual AST results.	
15.	Australian Scientific Technical Advisory Group – Antimicrobial Resistance Nil	
16.	Isolate and Data Requests	
16.1	Plan for AGAR Data in Children	
16.2	EXACT Study – Andrew Stewardson Alfred Hospital	
16.3	SNAP Study	
16.4	ECHINDA Study	
16.5	E. coli Qld 2015 – 2020 – Naomi Runnegar	
16.6	RCPAQA VVE request	
16.7	Pen S NHMRC Application (GC)	
16.8	TCH E. coli genotypic data – Frances Sheehan	
17.	New Business	
17.1	G. Coombs request* GC thanked the Executive for their approval to add a budget item for AGAR administration. GC will receive payment for 4 hours @ \$100 per hour per week.	

<p>17.2</p> <p>17.3</p>	<p>Reporting of Paediatric Bacteraemia Now that we have all the major Children’s Hospitals as AGAR contributors it was felt that we should include a Paediatric bacteraemia component into our reports. GC will ask Chris Blythe to chair a newly formed Paediatric Program Committee</p> <p>Reporting of EUCAST and CLSI breakpoints JB raised the issue of reporting only EUCAST breakpoints for the reports. It was decided to keep reporting both CLSI and EUCAST breakpoints due to the large number of labs still using CLSI.</p>	<p>GC</p>
	<p>Next Meeting There will be a face to face Committee meeting held in Sydney in August (either 16th or 20th) and an Executive meeting in November (date and venue TBA)</p>	